Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

FOR years, Emma Morris hid from cameras, avoided mirrors and felt like a prisoner in her own body because of her weight. But ...

The average weight loss with Zepbound per month may vary depending on the prescribed dosage. But after 72 weeks, or 18 months, someone using 15 mg of the drug as directed may be able to lose 20.9% ...

Zepbound is approved for weight loss and management, while Mounjaro is approved for the treatment of Type 2 diabetes. — Comorbidities. Mounjaro is approved for those with Type 2 diabetes.

People taking Zepbound were also more likely to reach specific weight loss targets than those taking Wegovy: About 32% of those taking Zepbound lost at least 25% of their body weight, compared ...

Zepbound, a weight loss drug by Eli Lily, received FDA approval. How the tirzepatide-containing drug works, potential side effects, and insurance coverage.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.